🇺🇸 JNJ 56021927 in United States

22 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 22

Most-reported reactions

1. Diarrhoea — 4 reports (18.18%)
2. Abdominal Pain — 3 reports (13.64%)
3. Pneumonia — 3 reports (13.64%)
4. Acute Coronary Syndrome — 2 reports (9.09%)
5. Asthenia — 2 reports (9.09%)
6. Cardiac Failure — 2 reports (9.09%)
7. Hypotension — 2 reports (9.09%)
8. Syncope — 2 reports (9.09%)
9. Acute Kidney Injury — 1 report (4.55%)
10. Acute Myocardial Infarction — 1 report (4.55%)

Source database →

Frequently asked questions

Is JNJ 56021927 approved in United States?

JNJ 56021927 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for JNJ 56021927 in United States?

Aragon Pharmaceuticals, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.